Janux Therapeutics Stock (NASDAQ:JANX)

Forecast Revenue Ownership Financials Chart

Previous Close

$24.31

52W Range

$21.97 - $71.71

50D Avg

$24.61

200D Avg

$33.30

Market Cap

$1.51B

Avg Vol (3M)

$775.08K

Beta

2.84

Div Yield

JANX Company Profile

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Jun 11, 2021

Website

JANX Performance

JANX Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	$10.59M	$8.08M	$8.61M
Operating Income	$-98.85M	$-72.98M	$-67.09M
Net Income	$-68.99M	$-58.29M	$-54.15M
EBITDA	$-98.85M	$-71.02M	$-66.25M
Basic EPS	$-1.28	$-1.32	$-1.31
Diluted EPS	$-1.28	$-1.32	$-1.31

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
MLYS	Mineralys Therapeutics, Inc.
JBIO	Jade Biosciences, Inc.
IPSC	Century Therapeutics, Inc.
ANEB	Anebulo Pharmaceuticals, Inc.
CLYM	Climb Bio, Inc.
DAWN	Day One Biopharmaceuticals, Inc.
GLUE	Monte Rosa Therapeutics, Inc.
EWTX	Edgewise Therapeutics, Inc.
INBX	Inhibrx Biosciences, Inc.